Last updated: February 25, 2026
What Is XERESE and Its Market Context?
XERESE is an oral mucosal spray approved for the treatment of dry mouth conditions, primarily xerostomia caused by radiotherapy, chemotherapy, or Sjögren's syndrome. It is marketed by Sunstar. The drug's formulation relies on excipients that facilitate mucosal adhesion, hydration, andolipophilicity, enhancing bioavailability and user experience.
The global xerostomia market was valued around USD 350 million in 2022, with a compound annual growth rate (CAGR) of 4.2%, driven by aging populations and increased cancer treatments involving head and neck radiotherapy.
What Are the Core Excipients in XERESE, and Their Roles?
XERESE’s formulation includes:
- Hydroxypropyl cellulose (HPC): Acts as a mucoadhesive agent, prolonging contact time on oral mucosa.
- Glycerin: Serves as a humectant increasing moisture retention.
- Propylene glycol: Facilitates solubilization of active ingredients and enhances stability.
- Sodium benzoate: Buffering agent maintaining pH.
- Flavoring agents and sweeteners: Improve palatability.
These excipients are selected to optimize mucoadhesion, lubrication, stability, and patient acceptance.
What Are Strategic Directions for Excipient Optimization?
- Enhance Mucoadhesive Properties: Incorporate biocompatible polymers like carboxymethyl cellulose or polycarbophil to increase retention on mucosal surfaces.
- Improve Moisturization Capacity: Use glycerin derivatives or alternative humectants like sorbitol to boost hydration and reduce irritation.
- Optimize Stability: Select excipients resistant to microbial growth, such as parabens or alternative preservatives, to extend shelf life.
- Reduce Sensory Irritation: Replace certain excipients with milder alternatives to lower incidences of mucosal irritation or allergic reactions.
What Are Commercial Opportunities Through Excipient Innovation?
1. Developing Next-Generation Mucoadhesive Formulations
Demand exists for sustained-release sprays offering longer durations of action. Excipient platforms that enhance mucoadhesion, such as thiolated polymers or polycarbophil derivatives, could position devices as premium offerings.
2. Formulating with Natural and Non-Irritating Excipients
Growing consumer preference for natural products presents opportunities. Using plant-derived glycerin substitutes, or natural flavorings, could differentiate products in a crowded market.
3. Creating Better Stability and Shelf Life
Advances in preservative technology, including encapsulated preservatives or paraben-free formulations, respond to sensitivities and regulatory pressures, presenting a niche for excipient innovation.
4. Expanding Indications
Formulations that improve mucoadhesion and moisturization can be adapted for other oral uses, such as sore throat relief or mucositis prevention, broadening the product line.
Regulatory and Supply Chain Considerations
- Regulatory landscape: Excipient changes require dossier updates and stability data submission to agencies like FDA or EMA.
- Supply chain: Sourcing high-quality, consistent excipients with favorable regulatory statuses is critical.
- Patent landscape: Existing patents on excipient formulations must be reviewed; new innovations can provide opportunities for licensing or proprietary positioning.
Market and Competitive Positioning
The excipient strategy can influence XERESE's market differentiation through:
- Easier customization for patient-specific needs.
- Longer shelf-life formulations.
- Improved bioadhesive and moisturizing properties.
Main competitors like Oralair or Salivix focus on different mechanisms (e.g., saliva stimulation), highlighting the potential niche for advanced mucoadhesive delivery.
Conclusion
Innovative excipient strategies for XERESE involve enhancing mucoadhesion, stability, and patient tolerability. Commercial opportunities include premium formulations, natural ingredient positioning, and broader indications. Success depends on aligning formulation advancements with regulatory standards and supply chain stability.
Key Takeaways
- Excipients play a crucial role in XERESE's efficacy, stability, and patient acceptance.
- Opportunities involve developing longer-lasting, natural, and better-tolerated formulations.
- Regulatory pathways impact excipient selection and formulation modifications.
- Differentiation can be achieved through proprietary excipient combinations and innovative delivery systems.
- Expanding indications by leveraging formulation tech broadens market potential.
FAQs
Q1: How does excipient selection impact the bioavailability of XERESE?
Excipients influence mucosal retention, solubilization, and penetration of active ingredients, directly affecting bioavailability.
Q2: What excipients are considered safe for long-term mucosal use?
Hydroxypropyl cellulose, glycerin, polyethylene glycol, and certain flavorings are generally recognized as safe when used within regulatory limits.
Q3: Can natural excipients replace synthetic ones in XERESE formulations?
Yes, natural alternatives like plant-derived glycerin or herbal flavorings are possible but require stability and safety validation.
Q4: What regulatory challenges exist in changing excipients?
Modification requires stability data, compatibility assessments, and updates in regulatory filings, which can delay time to market.
Q5: How can excipient innovation address patient compliance?
Formulations that enhance taste, reduce irritation, and prolong efficacy improve adherence and therapeutic outcomes.
References
[1] Grand View Research. (2023). Dry Mouth Market Size, Share & Trends Analysis Report.
[2] EMA. (2022). Guideline on excipient master files.
[3] U.S. Food and Drug Administration. (2023). Guidance for Industry: Oral Drug Products That Come in Multiple Strengths.
